Jump to content

Suritozole

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Rjwilmsi (talk | contribs) at 06:35, 4 May 2014 (Added 1 dois to journal cites using AWB (10090)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Suritozole
Clinical data
ATC code
  • none
Identifiers
  • 5-(3-fluorophenyl)-2,4-dimethyl-2,4-dihydro-3H-1,2,4-triazole-3-thione
CAS Number
PubChem CID
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H10FN3S
Molar mass223.269 g/mol g·mol−1
3D model (JSmol)
  • Cn1c(=S)n(C)nc1-c2cccc(F)c2
  (verify)

Suritozole (MDL 26,479) is an investigational cognition enhancer. It acts as a partial inverse agonist at the benzodiazepine receptor site on the GABAA ion channel complex, but does not have either anxiogenic or convulsant effects, unlike other BZD inverse agonists such as DMCM.[1] It was investigated for the treatment of depression and Alzheimer's disease,[2] but clinical development seems to have been discontinued.

References

  1. ^ Miller JA, Dudley MW, Kehne JH, Sorensen SM, Kane JM (September 1992). "MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist-like properties". Br. J. Pharmacol. 107 (1): 78–86. doi:10.1111/j.1476-5381.1992.tb14466.x. PMC 1907590. PMID 1330168.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ^ Robbins DK, Hutcheson SJ, Miller TD, Green VI, Bhargava VO, Weir SJ (May 1997). "Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers". Biopharm Drug Dispos. 18 (4): 325–34. doi:10.1002/(SICI)1099-081X(199705)18:4<325::AID-BDD21>3.0.CO;2-1. PMID 9158880.{{cite journal}}: CS1 maint: multiple names: authors list (link)